Cathy Eng, MD, shares her insight on the current paradigm of gastrointestinal cancers, specifically colorectal cancer and hepatocellular carcinoma.
The novel bispecific antibody ZW25 induced a disease control rate of 82% in heavily pretreated patients across several HER2-positive tumor types, according to phase I study results presented at the 2018 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.
Pixatimod (PG545) in combination with the PD-1 inhibitor nivolumab (Opdivo) may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.
Obesity is associated with an increased risk of early-onset colorectal cancer among women and correlates with higher rates of cancer resections in gastrointestinal malignancies across age groups.
Juan Manuel O’Connor, MD, discusses the final results of the CORRELATE regorafenib study in patients with metastatic colorectal cancer, emphasizing the importance of real-world data.
First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.
More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.
Heinz-Josef Lenz, MD, discusses the intersection between the molecular makeup of colorectal cancer and the development of novel therapies in the treatment paradigm.
Safety and efficacy findings for regorafenib in patients with previously treated metastatic colorectal cancer were consistent with previous phase III results.
Scott Kopetz, MD, PhD, FACP, discusses the current treatment landscape of colorectal cancer and the importance of molecular subtyping.